{"id":"insulin-aspart-novorapid","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin aspart is a genetically engineered insulin analog with a rapid onset of action (10–20 minutes) and short duration (3–5 hours). It mimics the body's natural insulin response to meals by binding to insulin receptors, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. Its rapid kinetics make it suitable for mealtime insulin therapy in both type 1 and type 2 diabetes.","oneSentence":"Insulin aspart is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:10.765Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02556840","phase":"NA","title":"Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-04-25","conditions":"Maturity-Onset Diabetes of the Young","enrollment":46},{"nctId":"NCT04149262","phase":"","title":"Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2019-11-15","conditions":"Type 1 Diabetes","enrollment":44},{"nctId":"NCT07387003","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2026-03-20","conditions":"Type 2 Diabetes (T2DM)","enrollment":300},{"nctId":"NCT05069545","phase":"","title":"A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-10-11","conditions":"Diabetes Mellitus, Type 1","enrollment":411},{"nctId":"NCT04698018","phase":"PHASE1","title":"A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-20","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":23},{"nctId":"NCT04588259","phase":"PHASE3","title":"Research Study to Compare a New Medicine \"Fast-acting Insulin Aspart\" to Another Medicine \"Insulin Aspart\" in Chinese People With Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-10-09","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":331},{"nctId":"NCT05417841","phase":"NA","title":"Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2023-03-23","conditions":"Type 2 Diabetes Mellitus","enrollment":218},{"nctId":"NCT05224258","phase":"NA","title":"Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2022-03-17","conditions":"Type 1 Diabetes","enrollment":240},{"nctId":"NCT04974528","phase":"PHASE3","title":"Afrezza® INHALE-1 Study in Pediatrics","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2021-09-29","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":319},{"nctId":"NCT03987802","phase":"","title":"An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-01-20","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":42},{"nctId":"NCT04042441","phase":"","title":"A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-07-29","conditions":"Diabetes Mellitus, Type 2","enrollment":1122},{"nctId":"NCT05221580","phase":"","title":"China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-03-18","conditions":"Diabetes Mellitus, Type 2","enrollment":887},{"nctId":"NCT06375031","phase":"PHASE1","title":"Comparison of HR011408 and NovoRapid® in Subjects With Diabetics","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-05","conditions":"Diabetes","enrollment":30},{"nctId":"NCT03874715","phase":"PHASE3","title":"Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-03-11","conditions":"Type 1 Diabetes Mellitus","enrollment":210},{"nctId":"NCT04460326","phase":"PHASE3","title":"Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2020-12-07","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":137},{"nctId":"NCT05754424","phase":"PHASE1","title":"AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study","status":"COMPLETED","sponsor":"Arecor Limited","startDate":"2023-02-27","conditions":"Diabetes Mellitus, Type 2","enrollment":41},{"nctId":"NCT05737576","phase":"PHASE1","title":"The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-03-20","conditions":"Diabetes","enrollment":61},{"nctId":"NCT00671008","phase":"","title":"Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-12","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":400},{"nctId":"NCT02491528","phase":"PHASE3","title":"A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and Safety","status":"COMPLETED","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2015-06-19","conditions":"Diabetes","enrollment":563},{"nctId":"NCT00101751","phase":"PHASE4","title":"INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":4877},{"nctId":"NCT01486862","phase":"PHASE4","title":"Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":26},{"nctId":"NCT00913497","phase":"PHASE4","title":"The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children","status":"COMPLETED","sponsor":"Corewell Health West","startDate":"2009-06","conditions":"Type 1 Diabetes Mellitus","enrollment":16},{"nctId":"NCT05726461","phase":"NA","title":"Efficacy and Safety of Android Artificial Pancreas System in Adult Patients With Type 1 Diabetes Mellitus in China","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2023-02-11","conditions":"Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders","enrollment":25},{"nctId":"NCT03770767","phase":"PHASE3","title":"Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2019-11-11","conditions":"Diabetes Mellitus, Pregnancy Complications","enrollment":216},{"nctId":"NCT03387787","phase":"PHASE2, PHASE3","title":"Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2018-01-30","conditions":"Type 2 Diabetes Mellitus","enrollment":15},{"nctId":"NCT05719961","phase":"PHASE1","title":"Bioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy Subjects","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-01-05","conditions":"Diabetes","enrollment":60},{"nctId":"NCT04655690","phase":"PHASE1","title":"A Study to Look at How Safe Insulin NNC0471-0119 is and How it Works in People With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-09","conditions":"Diabetes Mellitus, Type 1","enrollment":48},{"nctId":"NCT04892069","phase":"","title":"Investigating the Effect of Ryzodeg® in Adult Patients With Type 2 Diabetes in Lebanon","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-05-27","conditions":"Diabetes Mellitus, Type 2","enrollment":60},{"nctId":"NCT05184868","phase":"PHASE1","title":"AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study","status":"COMPLETED","sponsor":"Arecor Limited","startDate":"2022-01-03","conditions":"Diabetes Mellitus, Type 1","enrollment":24},{"nctId":"NCT04949867","phase":"PHASE4","title":"Dual-Hormone Closed-Loop Glucose Control in Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2021-05-20","conditions":"Type 1 Diabetes","enrollment":11},{"nctId":"NCT05221359","phase":"NA","title":"Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes","status":"RECRUITING","sponsor":"Defymed","startDate":"2022-05-05","conditions":"Type 1 Diabetes, Type 1 Diabetes Mellitus With Hypoglycemia","enrollment":8},{"nctId":"NCT00771693","phase":"PHASE4","title":"Effects of Insulin Treatment on Postprandial Platelet Activation in Patients With Non-insulin-dependent Diabetes Mellitus (NIDDM)","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2007-05","conditions":"Type 2 Diabetes Mellitus, Postprandial Hyperglycemia","enrollment":18},{"nctId":"NCT03436498","phase":"PHASE1","title":"Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-10","conditions":"Type 1 Diabetes Mellitus","enrollment":45},{"nctId":"NCT03202875","phase":"PHASE1","title":"A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-11-14","conditions":"Type 1 Diabetes","enrollment":30},{"nctId":"NCT03916601","phase":"PHASE1","title":"Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-12-13","conditions":"Type 1 Diabetes","enrollment":52},{"nctId":"NCT02910518","phase":"PHASE1","title":"A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-02-17","conditions":"Type1 Diabetes Mellitus","enrollment":44},{"nctId":"NCT03895515","phase":"","title":"Effect of Fiasp® in Type 1 Diabetes Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-01-03","conditions":"Diabetes Mellitus, Type 1","enrollment":178},{"nctId":"NCT03260868","phase":"PHASE4","title":"Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-09-19","conditions":"Type 1 Diabetes Mellitus","enrollment":15},{"nctId":"NCT03211858","phase":"PHASE3","title":"Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-08-02","conditions":"Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus","enrollment":597},{"nctId":"NCT03760068","phase":"PHASE3","title":"Mylan Insulin Aspart Study","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2018-11-07","conditions":"Diabetes Mellitus, Type 1","enrollment":478},{"nctId":"NCT03268005","phase":"PHASE3","title":"Research Study Comparing a New Medicine \"Fast-acting Insulin Aspart\" to Another Already Available Medicine \"NovoRapid\"/\"NovoLog\" in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-09-19","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1264},{"nctId":"NCT03416855","phase":"","title":"A Regulatory Post Marketing Surveillance (rPMS) Study of Ryzodeg® FlexTouch® (Insulin Degludec /Insulin Aspart) to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice in Korea","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-01-31","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":768},{"nctId":"NCT04656106","phase":"","title":"A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-27","conditions":"Diabetes Mellitus, Type 2","enrollment":200},{"nctId":"NCT03554486","phase":"PHASE4","title":"Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy","status":"COMPLETED","sponsor":"Stanford University","startDate":"2018-07-23","conditions":"Diabetes Mellitus, Type 1","enrollment":27},{"nctId":"NCT04660305","phase":"PHASE1","title":"AT278 and NovoRapid® in Glucose Clamp Study","status":"COMPLETED","sponsor":"Arecor Limited","startDate":"2020-12-02","conditions":"Diabetes Mellitus, Type 1","enrollment":38},{"nctId":"NCT03495908","phase":"NA","title":"Regular Insulin vs Rapid Insulin Delivered by V-Go","status":"COMPLETED","sponsor":"East Coast Institute for Research","startDate":"2018-04-09","conditions":"Type 2 Diabetes, Type 2 Diabetes Mellitus","enrollment":136},{"nctId":"NCT04409587","phase":"PHASE4","title":"Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump","status":"COMPLETED","sponsor":"Mountain Diabetes and Endocrine Center","startDate":"2018-04-12","conditions":"Type1 Diabetes Mellitus","enrollment":59},{"nctId":"NCT03981627","phase":"PHASE1, PHASE2","title":"A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Adocia","startDate":"2019-06-06","conditions":"Type 1 Diabetes Mellitus","enrollment":44},{"nctId":"NCT04414579","phase":"PHASE4","title":"The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus","status":"UNKNOWN","sponsor":"Mountain Diabetes and Endocrine Center","startDate":"2019-03-27","conditions":"Type 1 Diabetes Mellitus","enrollment":45},{"nctId":"NCT03977727","phase":"PHASE3","title":"FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump","status":"COMPLETED","sponsor":"Texas Diabetes & Endocrinology, P.A.","startDate":"2019-06-11","conditions":"Type 1 Diabetes Mellitus","enrollment":40},{"nctId":"NCT04079413","phase":"PHASE3","title":"Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Geropharm","startDate":"2019-06-03","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":264},{"nctId":"NCT03862690","phase":"","title":"A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2020-05-28","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT02846831","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 12 Days in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2019-01-24","conditions":"Type 1 Diabetes","enrollment":36},{"nctId":"NCT03449433","phase":"PHASE1","title":"A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-03-15","conditions":"Diabetes Mellitus, Type 1","enrollment":80},{"nctId":"NCT04226105","phase":"PHASE3","title":"Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients","status":"UNKNOWN","sponsor":"Geropharm","startDate":"2020-01-20","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus","enrollment":264},{"nctId":"NCT03450863","phase":"","title":"Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-03-22","conditions":"Diabetes, Diabetes Mellitus, Type 1 Diabetes","enrollment":320},{"nctId":"NCT04237129","phase":"PHASE1","title":"PK/PD Study of Gan & Lee Insulin Aspart Injection vs. US & EU NovoLog®/NovoRapid® in Healthy Males","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2019-08-27","conditions":"Diabetes Mellitus, Type 1","enrollment":36},{"nctId":"NCT03745157","phase":"","title":"RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-11-21","conditions":"Diabetes Mellitus, Type 2","enrollment":246},{"nctId":"NCT04184466","phase":"NA","title":"A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Aspart to NovoRapid® Penfill® in Healthy Subjects","status":"COMPLETED","sponsor":"Geropharm","startDate":"2018-10-18","conditions":"Clamp Study","enrollment":26},{"nctId":"NCT04184492","phase":"NA","title":"A Study to Compare Pharmacokinetics and Pharmacodynamics of GP-40081 to NovoMix® 30 Penfill® in Healthy Subjects","status":"COMPLETED","sponsor":"Geropharm","startDate":"2019-04-15","conditions":"Clamp Study","enrollment":34},{"nctId":"NCT02825251","phase":"PHASE3","title":"Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-07-06","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":472},{"nctId":"NCT02590016","phase":"PHASE4","title":"Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: A Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Tampere University Hospital","startDate":"2015-09","conditions":"Gestational Diabetes, Hypoglycemia, Neonatal","enrollment":50},{"nctId":"NCT02821052","phase":"","title":"Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-07-01","conditions":"Diabetes","enrollment":1355},{"nctId":"NCT03959514","phase":"PHASE1","title":"AT247, NovoRapid® and Fiasp® in Glucose Clamp Study","status":"COMPLETED","sponsor":"Arecor Limited","startDate":"2019-04-12","conditions":"Diabetes Mellitus, Type 1","enrollment":18},{"nctId":"NCT02846857","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 15 Weeks in Adolescents and Adults With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT03407599","phase":"PHASE1","title":"A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-01-08","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":46},{"nctId":"NCT02500706","phase":"PHASE3","title":"Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-05-04","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":1108},{"nctId":"NCT02582242","phase":"PHASE4","title":"Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-10-19","conditions":"Diabetes, Type 2 Diabetes Mellitus","enrollment":437},{"nctId":"NCT02670915","phase":"PHASE3","title":"Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-05-04","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":834},{"nctId":"NCT01194245","phase":"PHASE2","title":"Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2010-08","conditions":"Diabetes Mellitus, Type 1","enrollment":135},{"nctId":"NCT02004366","phase":"PHASE4","title":"Linagliptin Inpatient Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":295},{"nctId":"NCT01934712","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-08-30","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":50},{"nctId":"NCT02003677","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-11-29","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":67},{"nctId":"NCT01848990","phase":"PHASE4","title":"CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2013-03","conditions":"Type 1 Diabetes Mellitus","enrollment":456},{"nctId":"NCT00523042","phase":"PHASE3","title":"Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2007-08-30","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":10},{"nctId":"NCT00322257","phase":"PHASE3","title":"Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2006-05-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":596},{"nctId":"NCT03374774","phase":"","title":"A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-11-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":516},{"nctId":"NCT02219750","phase":"PHASE4","title":"Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2013-08","conditions":"Diabetes","enrollment":181},{"nctId":"NCT01680341","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-08-31","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":272},{"nctId":"NCT02276859","phase":"PHASE4","title":"Normal Versus Dual Wave Insulin Bolus for High-protein Food","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2014-10","conditions":"Type 1 Diabetes","enrollment":70},{"nctId":"NCT02488616","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 5 Days in Adults With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2018-03","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT00659282","phase":"","title":"Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-09-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":57610},{"nctId":"NCT03179332","phase":"PHASE1","title":"A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin Pump","status":"COMPLETED","sponsor":"Adocia","startDate":"2017-06-20","conditions":"Type1 Diabetes Mellitus","enrollment":43},{"nctId":"NCT03212950","phase":"NA","title":"Closed-Loop With Faster Aspart in Young Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Ljubljana, Faculty of Medicine","startDate":"2017-07-10","conditions":"Type 1 Diabetes Mellitus","enrollment":20},{"nctId":"NCT02490098","phase":"PHASE2","title":"Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2018-01","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT00574405","phase":"NA","title":"Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy","status":"COMPLETED","sponsor":"Arkansas Children's Hospital Research Institute","startDate":"2005-04","conditions":"Diabetes Mellitus","enrollment":24},{"nctId":"NCT03179280","phase":"NA","title":"Effect of Dual-wave Insulin Bolus on Postprandial Glycaemia","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2011-03","conditions":"Type1 Diabetes","enrollment":10},{"nctId":"NCT01845831","phase":"PHASE4","title":"Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-08","conditions":"Type 2 Diabetes","enrollment":292},{"nctId":"NCT00773279","phase":"PHASE3","title":"Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-09","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":242},{"nctId":"NCT01814137","phase":"PHASE3","title":"A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":40},{"nctId":"NCT00613951","phase":"PHASE2","title":"Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":182},{"nctId":"NCT01486966","phase":"PHASE4","title":"Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2011-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":58},{"nctId":"NCT02035371","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-01-13","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":41},{"nctId":"NCT00474045","phase":"PHASE3","title":"Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-05","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":470},{"nctId":"NCT01388361","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":413},{"nctId":"NCT00612040","phase":"PHASE2","title":"Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":178},{"nctId":"NCT00841087","phase":"PHASE2","title":"Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":65},{"nctId":"NCT00331604","phase":"PHASE3","title":"Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2006-08-31","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":618},{"nctId":"NCT00564668","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-06-19","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":126},{"nctId":"NCT01486914","phase":"PHASE1","title":"Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-01-19","conditions":"Diabetes, Healthy","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NovoRapid (Novo-Nordisk)"],"phase":"marketed","status":"active","brandName":"Insulin aspart (NovoRapid®)","genericName":"Insulin aspart (NovoRapid®)","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin aspart is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}